The agreement is aimed at strengthening Lupin’s diabetes portfolio and expanding its presence in the obesity segment. Bofanglutide injection, developed by Gan & Lee, is designed for adults with type 2 diabetes and also assists in weight management. Shares of Lupin Ltd ended at ₹2,082, down by ₹30.40, or 1.44%, on the BSE today, December 29.
